Inhibition of the metalloprotease ADAM19 as a novel senomorphic strategy to ameliorate gut permeability and senescence markers by modulating senescence-associated secretory phenotype (SASP).
The collective discussions demonstrate strong alignment and high interest, with phrases like 'novel strategy' and 'potential therapy' indicating excitement about scientific progress. The tone suggests recognition of the study's significance, especially among research-focused users who mention models and molecular targets, emphasizing both scientific curiosity and potential real-world impact.
AgreementModerate agreement
Most discussions reflect support or interest in the publication's findings, highlighting its novelty and potential. Words like 'promising,' 'innovative,' and emphasis on new strategies suggest agreement.
InterestHigh interest
The language and tone indicate high curiosity and enthusiasm, with several posts emphasizing benefits for aging and gut health, showing strong engagement.
EngagementModerate engagement
Posts reference specific methods such as models and genetic studies, indicating thoughtful consideration rather than superficial mentions.
ImpactModerate impact
The widespread sharing and focus on the therapeutic implications suggest perceived relevance and potential influence on aging research and therapies.
Abstract in brief
Inhibiting the metalloprotease ADAM19 shows promise as a new approach (senomorphic strategy) to improve gut health by reducing tissue permeability and markers of cell aging (senescence) through modulation of the SASP, a secretory profile associated with aging cells.
Researchers used a fly (Drosophila) model and genome-wide studies to identify ADAM19’s role in aging-related gut damage after radiation, finding that reducing ADAM19 levels decreased gut permeability, DNA damage, and senescence markers in flies.
Such findings were confirmed in mice and human cells, where inhibiting ADAM19 lowered SASP factors and inflammation, indicating it could be a potential target for developing anti-aging therapies affecting the gut and possibly other tissues.]
Inhibition of the metalloprotease ADAM19 as a novel senomorphic strategy to ameliorate gut permeability and senescence markers by modulating senescence-associated secretory phenotype (SASP)
https://t.co/RTQlBEJK99
Research demonstrates that inhibiting ADAM19, a metalloprotease, can improve gut permeability and reduce cellular aging markers by modulating the SASP. Studies in flies, mice, and human cells suggest ADAM19 as a…
Researchers at the Buck Institute identified ADAM19 as a key regulator of gut inflammation and cellular aging. Inhibiting ADAM19 reduced intestinal damage in model organisms and human cells, suggesting a promising…
#AgingResearch:
"Inhibition of the metalloprotease ADAM19 as a novel senomorphic strategy to ameliorate gut permeability and senescence markers by modulating senescence-associated secretory phenotype (SASP)"
#PressRelease ⬇️
www.aging-us.com/news-room/in...
#aging #press #openaccess #guthealth
#PaperoftheDay: "Inhibition of the metalloprotease ADAM19 as a novel senomorphic strategy to ameliorate gut permeability and senescence markers by modulating senescence-associated secretory phenotype (SASP)"
DOI ⬇️
https://t.co/AqBatYHn1C
#aging #research #oa #publishing
#AgingResearch:
"Inhibition of the metalloprotease ADAM19 as a novel senomorphic strategy to ameliorate gut permeability and senescence markers by modulating senescence-associated secretory phenotype (SASP)"
DOI ⬇️
doi.org/10.18632/aging.206224
#aging #research #openaccess #publishing
Inhibition of the metalloprotease ADAM19 as a novel senomorphic strategy to ameliorate gut permeability and senescence markers by modulating senescence-associated secretory phenotype (SASP)
https://t.co/RTQlBEJK99
@kapahi_pankaj and lab members proved that inhibition of the metalloprotease ADAM19 is a novel senomorphic strategy to ameliorate gut permeability and #senescence markers by modulating senescence-associated secretory phenotype (#SASP)
https://t.co/8Y9YQWT3X0 https://t.co/qtbhWelWNc
Inhibition of the metalloprotease ADAM19 as a novel senomorphic strategy to ameliorate gut permeability and senescence markers by modulating senescence-associated secretory phenotype (SASP)
https://t.co/V4wLwyCyTZ
Inhibition of the metalloprotease ADAM19 as a novel senomorphic strategy to ameliorate gut permeability and senescence markers by modulating senescence-associated secretory phenotype (SASP)
#Drosophila
Inhibition of the metalloprotease ADAM19 as a Novel Senomorphic Strategy to Ameliorate gut permeability and senescence markers by modulating senescence-associated secretory phenotype (SASP) https://www.biorxiv.org/content/10.1101/2024.12.16.628718v1
Inhibition of the metalloprotease ADAM19 as a Novel Senomorphic Strategy to Ameliorate gut permeability and senescence markers by modulating senescence-associated secretory phenotype (SASP) https://www.biorxiv.org/content/10.1101/2024.12.16.628718v1
Inhibition of the metalloprotease ADAM19 as a Novel Senomorphic Strategy to Ameliorate gut permeability and senescence markers by ... https://t.co/LSKmOJ1TWd #biorxiv_molbio